Compare Pfizer Inc (PFE) vs Vanguard Global ex-US Real Estate Index Fd ETF (VNQI) Price & Performance

Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a neutral technical outlook. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.75 beating expectations of $0.722. Pfizer demonstrates robust profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated from pandemic peaks. Recent news highlights the company's focus on AI drug discovery and pipeline development.

Pfizer presents a value opportunity trading below analyst consensus target of $28.25, with 38% of analysts rating it Buy. The stock offers a solid dividend yield with recent $0.43 payments. Key risks include patent expirations and revenue normalization post-COVID, while catalysts include obesity and oncology pipeline developments in 2026.

VNQI (Vanguard Global ex-U.S. Real Estate ETF) trades at $45.69, showing minimal daily movement with a slight 0.07% decline. The technical picture remains bearish with moving averages signaling caution, though oscillators are neutral. The fund provides international real estate diversification with 682 holdings across 30+ countries, featuring a low 0.12% expense ratio and attractive 4.6% dividend yield. Recent analysis highlights its role as a cost-effective diversifier for U.S.-focused real estate portfolios.

VNQI offers exposure to recovering global real estate markets with transaction volumes expected to grow over 10% in 2026. The fund trades at attractive valuations (0.9x P/B, 11.9x P/E) but faces headwinds from international market volatility and currency risks. While providing yield advantages over domestic peers, its total returns have lagged, making it suitable for investors seeking international diversification and income rather than growth leadership.